Phreesia executive sells shares worth over $570

Phreesia, Inc. (NYSE:PHR ) executive David Linetsky, who serves as the company's Senior Vice President of Life Sciences, has recently sold a portion of his stock in the company. The transaction involved the sale of 24 shares at a price of $24.0433 each, totaling over $570.

This sale, which took place on September 19, 2024, was executed under the company's mandatory sell-to-cover policy, which is designed to cover tax withholding obligations related to the settlement of an award of restricted stock units. It is important to note that these transactions are non-discretionary and are part of the company's standard procedures for handling tax obligations arising from employee stock awards.

Following the sale, Linetsky's direct holdings in Phreesia, Inc. decreased, but he still retains a significant number of shares indirectly through his spouse. The total number of shares owned by him following the transaction is 8,971, in addition to the 203,318 shares held directly.

Investors and stakeholders often keep a close eye on insider transactions as they can provide insights into executives' perspectives on the company's current valuation and future prospects. However, it is also common for executives to sell shares for personal financial planning, diversification, and other non-company-related reasons.

Phreesia, Inc., known for its innovative healthcare software solutions, has not provided any additional comments on this transaction. The details of the sale were made public through a Form 4 filing with the Securities and Exchange Commission, which is a requirement for company insiders to report their trading activities.



In other recent news, Phreesia Inc . has been the focus of several financial services firms following its robust second-quarter revenue, which showed a 19% year-over-year increase. The company also reported a positive EBITDA of $7 million, a significant improvement from the previous year, surpassing the consensus estimate. Notably, Baird raised its price target for Phreesia to $34, maintaining an Outperform rating on the stock. Other firms such as Truist Securities and Piper Sandler also expressed a positive outlook, with Truist raising its price target to $31 and Piper Sandler maintaining a consistent price target of $30.

In addition to these upgrades, Canaccord Genuity and Needham maintained their respective ratings and price targets for Phreesia, highlighting the company's operational efficiency and focus on long-term profitability. Phreesia's recent financial results and future growth indicators have contributed to these decisions, reflecting confidence in the company's financial trajectory and market performance.

These developments come as Phreesia maintains its revenue outlook for fiscal year 2025 and raises its EBITDA forecast, signaling a shift towards sustained profitable growth. The company's recent financial performance and updates from various analyst firms are among the recent developments that investors should note.
InvestingPro Insights


As Phreesia, Inc. (NYSE:PHR) continues to navigate the healthcare software solutions market, recent activity from company insiders has caught the attention of investors. In light of the recent sale of shares by executive David Linetsky, it's important to consider the company's current financial health and market performance to understand the broader context.

According to InvestingPro, eight analysts have revised their earnings upwards for the upcoming period, signaling a potential positive outlook on the company's performance. This optimism, however, is contrasted by the anticipation that Phreesia will not be profitable this year, as noted by the same analysts. Despite not being profitable over the last twelve months, Phreesia has seen a strong return over the last three months, with an 18.74% increase in its share price.

InvestingPro Data further reveals that Phreesia operates with a moderate level of debt and does not pay a dividend to shareholders. The company's market capitalization stands at $1.37 billion, and while it holds a negative P/E ratio of -13.33, this is indicative of the challenges many growth-oriented companies face in achieving profitability. Phreesia has also demonstrated a robust revenue growth rate of 22.1% in the last twelve months as of Q2 2025, which may be a factor in the analysts' positive earnings revisions.

For those interested in further insights, InvestingPro offers additional tips on Phreesia, Inc. These tips can provide a deeper understanding of the company's financials and market position, which could be particularly valuable in light of insider trading activities. To explore these insights, check out the tips available on InvestingPro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Source: Investing.com